Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in thrombolytic therapy

D M Rutkowski, W S Burkle

    Drug Intelligence & Clinical Pharmacy
    |February 1, 1982
    PubMed
    Summary

    Streptokinase and urokinase are thrombolytic drugs that dissolve blood clots by converting plasminogen to plasmin. While effective in clinical trials, their use is limited by an increased bleeding risk, necessitating careful patient selection.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Cimetidine's low price: can we afford it?

    American journal of hospital pharmacy·1990
    Same author

    Development and implementation of clinical pharmacokinetic services.

    American journal of hospital pharmacy·1990
    Same author

    Is tobramycin less nephrotoxic than gentamicin?

    Clinical pharmacy·1986
    Same author

    Cyclosporine pharmacokinetics and blood level monitoring.

    Drug intelligence & clinical pharmacy·1985
    Same author

    Usefulness of cyclosporine monitoring questioned.

    Clinical pharmacy·1984
    Same author

    Evaluation of the Chiou method for determining theophylline dosages.

    Clinical pharmacy·1984

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology

    Background:

    • Thrombolytic agents like streptokinase and urokinase are crucial in treating thromboembolic disorders.
    • These drugs function by activating the fibrinolytic system, converting plasminogen to plasmin.

    Purpose of the Study:

    • To review the efficacy and risks associated with streptokinase and urokinase in clinical practice.
    • To highlight the mechanism of action and therapeutic applications of these thrombolytic agents.

    Main Methods:

    • Analysis of recent clinical trials involving thrombolytic therapy.
    • Comparison of thrombolytic agents with anticoagulants like heparin.

    Main Results:

    • Thrombolytic agents demonstrated significantly greater clot lysis compared to heparin alone in various conditions.
    • Pulmonary emboli, deep vein thrombosis, arterial thrombosis, and cannula occlusions showed improved outcomes with thrombolytics.

    Conclusions:

    • Thrombolytic therapy offers significant advantages in dissolving thrombi but carries an increased risk of bleeding.
    • Contraindications are extensive, emphasizing the need to weigh benefits against risks for each patient.

    Related Experiment Videos